Scarica l'app Stockscreener
3.25
0.62%
0.02
Dopo l'orario di chiusura:
3.26
0.010
+0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.23
Aprire:
$3.31
Volume 24 ore:
3.10M
Relative Volume:
0.81
Capitalizzazione di mercato:
$280.19M
Reddito:
$7.62M
Utile/perdita netta:
$-271.60M
Rapporto P/E:
-0.9281
EPS:
-3.5018
Flusso di cassa netto:
$-271.54M
1 W Prestazione:
-10.22%
1M Prestazione:
-32.15%
6M Prestazione:
-75.75%
1 anno Prestazione:
-75.93%
Intervallo 1D:
$3.10
$3.31
Intervallo di 1 settimana:
$3.10
$3.60
Portata 52W:
$3.10
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Nome
Eyepoint Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
3.25 | 312.09M | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Inc Borsa (EYPT) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - PR Newswire
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - Kalkine
Long term debt to total assets ratio of EyePoint, Inc. – HAN:PV3B - TradingView
PV3B Stock Price and Chart — HAN:PV3B - TradingView
Two Worcester County Firms Part of $40M Life Sciences Awards - This Week in Worcester
EyePoint, Inc. Actuals & Estimates (HAN:PV3B) - TradingView
EyePoint Pharmaceuticals Inc (PV3B.MU) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - Stocktwits
EyePoint, Inc. (EYPT) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
EyePoint faces securities fraud probe after Pha... - Pluang
EyePoint Pharmaceuticals Inc (EYPT) Stock Price Target & Forecast - TradingKey
EyePoint, Inc. (EYPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
EyePoint Pharmaceuticals stock holds near its yearly range - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages EyePoint, Inc. (EYPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against EyePoint, Inc. (EYPT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
EyePoint, Inc. (EYPT) Stock Analysis: Exploring A Potential 549% Upside For Investors - DirectorsTalk Interviews
EyePoint, Inc. (EYPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against EyePoint, Inc. (EYPT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
EYPT Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Edge HigherRevenue Breakdown Analysis - careplusvn.com
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
EyePoint Inc at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against EyePoint, Inc. (EYPT) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) - The Globe and Mail
EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead - Investing.com Canada
EyePoint posts updated presentation showing LUGANO Phase 3 DURAVYU topline results, NDA path to H1 2027 - TradingView
Eye drug cuts injections 42% in EyePoint (EYPT) trial but misses its main goal - Stock Titan
EyePoint Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com India
INVESTIGATION ALERT: Investigation Launched Into EyePoint, Inc. (EYPT), Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - Barchart.com
Investment firm discloses double-digit stake in EyePoint (EYPT) - Stock Titan
EyePoint's stock plunges 66% after failed Phase 3 trial for wet AMD treatment. - Pluang
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm - GlobeNewswire Inc.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - finance.yahoo.com
EyePoint faces securities fraud probe after tri... - Pluang
Eyepoint Pharmaceuticals Inc (EYPT) Peer Comparison – Compare with Others - Value Research
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals - GlobeNewswire
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
EyePoint stock drops as TD Cowen downgrades (EYPT:NASDAQ) - Seeking Alpha
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20 - marketscreener.com
EyePoint Announces Upcoming Investor Conference and Retina Society Presentations - Quiver Quantitative
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - marketscreener.com
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com Canada
TD Cowen downgrades EyePoint stock to Hold on trial concerns - investing.com
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm - Sahm
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - financialcontent.com
Eyepoint Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):